272 related articles for article (PubMed ID: 16687057)
1. Progressive multifocal leukoencephalopathy: lessons from AIDS and natalizumab.
Berger JR; Houff S
Neurol Res; 2006 Apr; 28(3):299-305. PubMed ID: 16687057
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibodies and progressive multifocal leukoencephalopathy.
Berger JR; Houff SA; Major EO
MAbs; 2009; 1(6):583-9. PubMed ID: 20073129
[TBL] [Abstract][Full Text] [Related]
3. The link between VLA-4 and JC virus reactivation.
Monaco MC; Major EO
Expert Rev Clin Immunol; 2012 Jan; 8(1):63-72. PubMed ID: 22149341
[TBL] [Abstract][Full Text] [Related]
4. The pathogenesis of progressive multifocal leukoencephalopathy.
Berger JR; Khalili K
Discov Med; 2011 Dec; 12(67):495-503. PubMed ID: 22204766
[TBL] [Abstract][Full Text] [Related]
5. Progressive multifocal leukoencephalopathy and newer biological agents.
Berger JR
Drug Saf; 2010 Nov; 33(11):969-83. PubMed ID: 20925435
[TBL] [Abstract][Full Text] [Related]
6. Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidence.
Bacchetta F; Mathias A; Schluep M; Du Pasquier R
Mult Scler; 2017 Feb; 23(2):300-303. PubMed ID: 28165319
[TBL] [Abstract][Full Text] [Related]
7. Reactivation of JC virus and development of PML in patients with multiple sclerosis.
Khalili K; White MK; Lublin F; Ferrante P; Berger JR
Neurology; 2007 Mar; 68(13):985-90. PubMed ID: 17389301
[TBL] [Abstract][Full Text] [Related]
8. JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy?
Verbeeck J; Van Assche G; Ryding J; Wollants E; Rans K; Vermeire S; Pourkarim MR; Noman M; Dillner J; Van Ranst M; Rutgeerts P
Gut; 2008 Oct; 57(10):1393-7. PubMed ID: 18436577
[TBL] [Abstract][Full Text] [Related]
9. Review of progressive multifocal leukoencephalopathy and natalizumab.
Aksamit AJ
Neurologist; 2006 Nov; 12(6):293-8. PubMed ID: 17122725
[TBL] [Abstract][Full Text] [Related]
10. The human JC polyomavirus (JCPyV): virological background and clinical implications.
Hirsch HH; Kardas P; Kranz D; Leboeuf C
APMIS; 2013 Aug; 121(8):685-727. PubMed ID: 23781977
[TBL] [Abstract][Full Text] [Related]
11. Progressive multifocal leukoencephalopathy and rheumatoid arthritis treatments.
Clavel G; Moulignier A; Semerano L
Joint Bone Spine; 2017 Dec; 84(6):671-675. PubMed ID: 28323224
[TBL] [Abstract][Full Text] [Related]
12. Advances in the management of PML: focus on natalizumab.
Fox R
Cleve Clin J Med; 2011 Nov; 78 Suppl 2():S33-7. PubMed ID: 22123933
[TBL] [Abstract][Full Text] [Related]
13. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
Trampe AK; Hemmelmann C; Stroet A; Haghikia A; Hellwig K; Wiendl H; Goelz S; Ziegler A; Gold R; Chan A
Neurology; 2012 May; 78(22):1736-42. PubMed ID: 22592369
[TBL] [Abstract][Full Text] [Related]
14. Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain.
Ferenczy MW; Marshall LJ; Nelson CD; Atwood WJ; Nath A; Khalili K; Major EO
Clin Microbiol Rev; 2012 Jul; 25(3):471-506. PubMed ID: 22763635
[TBL] [Abstract][Full Text] [Related]
15. Natalizumab has no direct biological effect on JC virus infectivity in permissive human neural cell lines.
Suzuki T; Yamanouchi S; Sunden Y; Orba Y; Kimura T; Sawa H
J Med Virol; 2010 Jul; 82(7):1229-35. PubMed ID: 20513089
[TBL] [Abstract][Full Text] [Related]
16. Progressive multifocal leukoencephalopathy in anti-CD20 and other monoclonal antibody (mAb) therapies used in multiple sclerosis: A review.
Sharma K; Tolaymat S; Yu H; Elkhooly M; Jaiswal S; Jena A; Kakara M; Sriwastava S
J Neurol Sci; 2022 Dec; 443():120459. PubMed ID: 36283150
[TBL] [Abstract][Full Text] [Related]
17. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
[TBL] [Abstract][Full Text] [Related]
18. Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy.
Carruthers RL; Chitnis T; Healy BC
Mult Scler; 2014 May; 20(6):757-60. PubMed ID: 24189572
[TBL] [Abstract][Full Text] [Related]
19. Progressive multifocal leukoencephalopathy in acquired immunodeficiency syndrome: explaining the high incidence and disproportionate frequency of the illness relative to other immunosuppressive conditions.
Berger JR
J Neurovirol; 2003; 9 Suppl 1():38-41. PubMed ID: 12709870
[TBL] [Abstract][Full Text] [Related]
20. [[Natalizumab therapy, 2013].
Karácsony M; Bencsik K; Vécsei L
Ideggyogy Sz; 2014 Jul; 67(7-8):220-8. PubMed ID: 25509362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]